Founded 1960s Area served Worldwide Parent organization Humuza Consultants | Founder Habil Khorakiwala Headquarters Mumbai | |
 | ||
Type Public company (NSE: WOCKPHARMA) Industry Pharmaceuticals
Health care Key people Habil Khorakiwala (Chairman)
Murtaza Khorakiwala (managing director)
Huzaifa Khorakiwala (Executive Director) Stock price WOCKPHARMA (NSE) ₹ 766.00 +46.75 (+6.50%)3 Apr, 3:46 PM IST - Disclaimer CEO Murtaza Khorakiwala (Apr 2009–) Revenue 46.14 billion INR (US$690 million) Profiles | ||
Wockhardt journey sand art
Wockhardt Ltd. is a pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe. In 2011–2012 its UK and USA sales alone were US$475 million. It has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. The Company has a market capitalisation of over ₹211 billion (US$3.1 billion) and an annual turnover of ₹36 billion (US$530 million). It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company employs over 8,600 people globally. Wockhardt Hospitals is a subsidiary of the Wockhardt Group.
Contents
Sun pharma vs wockhardt
History
Wockhardt was founded by Habil Khorakiwala in the 1960s. His father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works in 1959. This was incorporated as Wockhardt Pvt. Ltd., in 1973. Wockhardt Ltd. was incorporated on July 8.1999. Wockhardt is often confused as a multinational because of its German-sounding name.
Wockhardt is the first company outside the US and Europe to manufacture recombinant human insulin.
Acquisitions and subsidiaries
Wockhardt's acquisitions include Wallis Laboratory, UK (1998), Merind, India (1998), CP Pharmaceuticals, UK (2003), Espharma GmbH, Germany (2004), Dumex India (2006), Pinewood Laboratory, Ireland (2006), Morton Grove, US (2007), and Negma, France (2007). Wockhardt's debt following the acquisitions was close to Rs 38 billion, and Habil Khorakiwala quit as managing director. The board of directors, on 31 March 2009 approved the appointments of Habil Khorakiwala's sons Murtaza Khorakiwala and Hozaifa Khorakiwala as managing director and Executive Director respectively.
Good Manufacturing Practice violations
Wockhardt received a FDA warning letter 25 November 2013 identifying significant violations of current good manufacturing practice for finished pharmaceuticals at the Chikalthana and Wiluj facilities.
A warning letter sent 18 July 2013 referring to an 18 March inspection of the Waluj facility, Aurangabad cited repeatedly delayed, denied or limited an FDA inspection. Citations included destruction of raw analytical data, destruction of analytical samples, lying by both the production head and vice-president of Manufacturing to the FDA Inspector.
Specific GMP violations included failure to prepare batch production records for drug products, attempts to hide manufacturing for the USA market from inspection, use of 'trial' analyses and 'official' analyses to attempt to hide failing or out of specification results, inability to demonstrate integrity of computer records, no audit system for computer records, faked training records for critical GMP activities, and inadequate washing and toilet facilities.